NCT00490035已完成3 期
A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 399
- 试验地点
- 76
- 主要终点
- Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period
研究概览
简要总结
This study will evaluate the efficacy and safety of Brivaracetam to support the submission file in the indication of adjunctive treatment in adolescents and adults with partial onset seizures.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 16 Years 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects were from 16 to 70 years, both inclusive. Subjects under 18 years of age were only included where legally permitted and ethically accepted
- •Subjects with well-characterized focal epilepsy or epileptic syndrome according to the International League Against Epilepsy (ILAE) classification
- •Subjects had a history of partial onset seizures (POS) whether or not secondarily generalized (Type I seizures according to the ILAE classification)
- •Subjects had at least 2 POS whether or not secondarily generalized per month during the 3 months preceding Visit 1
- •Subjects had at least 8 POS whether or not secondarily generalized during the 8-Week Baseline Period
- •Subjects were uncontrolled while treated by 1 to 2 permitted concomitant antiepileptic drugs (AEDs). Vagal nerve stimulation was allowed and was not counted as a concomitant AED
排除标准
- •History or presence of seizures occurring only in clusters (too frequently or indistinctly separated to be reliably counted) before Visit 3
- •History or presence of status epilepticus during the year preceding Visit 1 or during Baseline
研究组 & 干预措施
Placebo
Placebo Comparator
Matching Placebo tablets administered twice a day
干预措施: Placebo (Other)
Brivaracetam 20 mg/day
Experimental
Brivaracetam 20 mg/day, 10 mg administered twice a day
干预措施: Brivaracetam (Drug)
Brivaracetam 50 mg/day
Experimental
Brivaracetam 50 mg/day, 25 mg administered twice a day
干预措施: Brivaracetam (Drug)
Brivaracetam 100 mg/day
Experimental
Brivaracetam 100 mg/day, 50 mg administered twice a day
干预措施: Brivaracetam (Drug)
结局指标
主要结局
Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period
时间窗: From Baseline to 12-week Treatment Period
Partial (Type I) Seizures can be classified into one of the following three groups: Simple Partial Seizures, Complex Partial Seizures, Partial Seizures evolving to Secondarily Generalized Seizures.
次要结局
- Categorized Percentage Change From Baseline in Seizure Frequency for Partial Onset Seizure (Type I) Over the 12-week Treatment Period(From Baseline to 12-week Treatment Period)
- Time to Fifth Type I Seizure During the 12-week Treatment Period(From Baseline to 12-week Treatment Period)
- Change From Baseline to the 12-week Treatment Period in Cognitive Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score(From Baseline to 12-week Treatment Period)
- Responder Rate for Partial Onset Seizures (Type I) Frequency Per Week Over the 12-week Treatment Period(From Baseline to 12-week Treatment Period)
- Seizure Freedom Rate (All Seizure Types) Over the 12-week Treatment Period(From Baseline to 12-week Treatment Period)
- Patient's Global Evaluation Scale (P-GES) Evaluated at Last Visit or Early Discontinuation Visit(Last Visit or Early Discontinuation Visit in the 12-week Treatment Period)
- Change From Baseline to the 12-week Treatment Period in Overall Quality of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score(From Baseline to 12-week Treatment Period)
- Time to First Type I Seizure During the 12-week Treatment Period(From Baseline to 12-week Treatment Period)
- Time to Tenth Type I Seizure During the 12-week Treatment Period(From Baseline to 12-week Treatment Period)
- Change From Baseline to the 12-week Treatment Period in Daily Activities/Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score(From Baseline to 12-week Treatment Period)
- Change From Baseline to the 12-week Treatment Period in Emotional Well-Being Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score(From Baseline to 12-week Treatment Period)
- Change From Baseline to the 12-week Treatment Period in Medication Effects Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score(From Baseline to 12-week Treatment Period)
- All Seizure Frequency (Type I+II+III) Per Week Over the 12-week Treatment Period(From Baseline to 12-week Treatment Period)
- Percent Change From Baseline to the 12-week Treatment Period in Partial Onset Seizure (Type I) Frequency Per Week(From Baseline to 12-week Treatment Period)
- Reduction of Type IC/Type I Seizure Frequency Ratio From Baseline to the 12- Week Treatment Period.(From Baseline to 12-week Treatment Period)
- Change From Baseline to the 12-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score(From Baseline to 12-week Treatment Period)
- Change From Baseline to the 12-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score(From Baseline to 12-week Treatment Period)
- Change From Baseline to the 12-week Treatment Period in Hospital Anxiety Score(From Baseline to 12-week Treatment Period)
- Investigator's Global Evaluation Scale (I-GES) Evaluated at Last Visit or Early Discontinuation Visit(Last Visit or Early Discontinuation Visit in the 12-week Treatment Period)
- Change From Baseline to the 12-week Treatment Period in Energy/Fatigue Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score(From Baseline to 12-week Treatment Period)
- Change From Baseline to the 12-week Treatment Period in Hospital Depression Score(From Baseline to 12-week Treatment Period)
- Change From Baseline to the 12-week Treatment Period in Health Status of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score(From Baseline to 12-week Treatment Period)
研究者
研究点 (76)
Loading locations...
相似试验
已完成
3 期
Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset SeizuresEpilepsyNCT00464269UCB Pharma400
已完成
2 期
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.EpilepsyNCT00175825UCB Pharma210
已完成
3 期
This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam TreatmentEpilepsyNCT00150800UCB PHARMA Inc. (US)668
已完成
2 期
A Study of Brivaracetam in Subjects With Partial Onset SeizuresEpilepsy, FocalNCT00175929UCB Pharma157
已完成
3 期
A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary GeneralizationPartial Seizures With or Without Secondary GeneralizationEpilepsyNCT03685630UCB Biopharma S.P.R.L.10